• Adagio Medical received a Nasdaq notice for failing the $1 minimum bid-price rule following 30 straight business days below $1.
• Shares remain listed on the Nasdaq Capital Market; the company has until Dec. 9, 2026 to regain compliance.
• Compliance requires a close at or above $1 for at least 10 consecutive trading days.
• Adagio is weighing options; a second 180-day cure period may be available, including a reverse stock split.
• Failure to regain compliance could trigger a delisting notice if it does not qualify for or meet the extended deadline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-073517), on June 12, 2026, and is solely responsible for the information contained therein.